{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:15:24Z","timestamp":1781212524319,"version":"3.54.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Migraine is a debilitating neurological disorder, with a wide range of symptoms and disease burden, underscoring the heterogeneity of patients\u2019 disease characteristics and treatment needs. To characterize the profile of migraine patients in the US who may be eligible for preventive treatment with an anti-CGRP pathway mAb and to better understand treatment patterns and real-world use of acute and preventive medications for migraine, we conducted a retrospective cohort study of adult patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>These patients were identified as having migraine using diagnosis codes or migraine-specific medication use (first\u2009=\u2009index) in the IQVIA PharMetrics\u00ae Plus database. Patients were required to have \u2265\u200912\u2009months of continuous enrollment in medical and pharmacy benefits prior to index (baseline) and after index (follow-up). Patients were stratified into chronic migraine (CM) and non-chronic migraine (non-CM) by diagnosis codes. Based on acute migraine-specific medication dispensing data in the follow-up period, non-CM patients were divided into 3 cohorts: highest, middle, and lowest tertile of total units of dispensed acute migraine-specific medication (gepants, ditans, ergot derivatives, and triptans). Migraine medication use was captured in the baseline and follow-up periods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 22,584\u2009CM and 216,807 non-CM patients (72,269 patients in each tertile) were identified and included in the study. Over the follow-up, CM patients had a mean of 70 units of acute migraine-specific medications dispensed, while the highest, middle, and lowest tertile of non-CM patients had a mean of 92, 29, and 10\u2009units, respectively. Anti-calcitonin gene-related peptide pathway mAbs were dispensed for 28.9% of CM patients, and for 6.9%, 4.1%, and 2.9% of non-CM patients in the highest, middle, and lowest tertiles, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A lower proportion of non-CM patients had use of anti-calcitonin gene-related peptide pathway mAbs compared to CM patients, confirming the unmet need with appropriate preventive medication. There appears to be a persistent gap in management of patients without a diagnosis of CM who are dispensed high quantities of acute migraine-specific medications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1433423","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T04:33:18Z","timestamp":1722918798000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment patterns of patients with migraine eligible for anti-CGRP pathway monoclonal antibodies"],"prefix":"10.3389","volume":"15","author":[{"given":"Ani C.","family":"Khodavirdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasjit K.","family":"Multani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam S.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiston","family":"Vuvu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Bensink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Stockl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chun","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Laine","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart J.","family":"Tepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/head.14151","article-title":"Learning the full impact of migraine through patient voices: a qualitative study","volume":"61","author":"Estave","year":"2021","journal-title":"Headache"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","article-title":"Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study","volume":"59","author":"Buse","year":"2019","journal-title":"Headache"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jama.2021.21857","article-title":"What is migraine?","volume":"327","author":"Walter","year":"2022","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s10194-024-01712-7","article-title":"Health equity, care access and quality in headache \u2013 part 1","volume":"25","author":"Tana","year":"2024","journal-title":"J Headache Pain"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/head.14259","article-title":"Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study","volume":"62","author":"Lipton","year":"2022","journal-title":"Headache"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/head.14024","article-title":"The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic\u2010specific estimates from government health surveys","volume":"61","author":"Burch","year":"2021","journal-title":"Headache"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12955-016-0542-3","article-title":"Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches","volume":"14","author":"Mannix","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.13829","article-title":"United States patients\u2019 perspective of living with migraine: country-specific results from the global \u201cmy migraine voice\u201d survey","volume":"60","author":"Gibbs","year":"2020","journal-title":"Headache"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/head.14289","article-title":"Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States","volume":"62","author":"Harris","year":"2022","journal-title":"Headache"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1111\/head.13966","article-title":"Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American migraine prevalence and prevention (AMPP) study","volume":"60","author":"Buse","year":"2020","journal-title":"Headache"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/head.14154","article-title":"Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency","volume":"61","author":"Ishii","year":"2021","journal-title":"Headache"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American headache society consensus statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"Ailani","year":"2021","journal-title":"Headache"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","article-title":"Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis","volume":"37","author":"Hepp","year":"2017","journal-title":"Cephalalgia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01699-7","article-title":"167","volume":"24","author":"Raffaelli","year":"2023","journal-title":"J Headache Pain"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","article-title":"Defining the differences between episodic migraine and chronic migraine","volume":"16","author":"Katsarava","year":"2012","journal-title":"Curr Pain Headache Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","article-title":"Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study","volume":"48","author":"Bigal","year":"2008","journal-title":"Headache"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0333102415593088","article-title":"Treatment of medication-overuse headache: a systematic review","volume":"36","author":"Chiang","year":"2016","journal-title":"Cephalalgia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e1409","DOI":"10.1212\/WNL.0000000000200117","article-title":"Patient-centered treatment of chronic migraine with medication overuse: a prospective, randomized, pragmatic clinical trial","volume":"98","author":"Schwedt","year":"2022","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)","volume":"53","author":"Blumenfeld","year":"2013","journal-title":"Headache"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40120-021-00245-4","article-title":"Real-world treatment profiles, clinical outcomes, and healthcare resource utilization of patients with migraine prescribed Erenumab: a multicenter chart-review study of US headache centers","volume":"10","author":"Faust","year":"2021","journal-title":"Neurol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","article-title":"Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update","volume":"64","author":"Charles","year":"2024","journal-title":"Headache"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/wnl.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: Table 1","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The international classification of headache disorders, 3rd edition (beta version)","volume":"33","year":"2013","journal-title":"Cephalalgia"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"jnnp-2023-333295","DOI":"10.1136\/jnnp-2023-333295","article-title":"Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world","author":"Caronna","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1433423\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T04:33:20Z","timestamp":1722918800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1433423\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":25,"alternative-id":["10.3389\/fneur.2024.1433423"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1433423","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"article-number":"1433423"}}